Treatment of pruritus of primary biliary cirrhosis with rifampin
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Pruritus can be a debilitating symptom in patients with chronic cholestasis. Based on previous reports of its efficacy, we evaluated the impact of rifampin on the pruritus associated with primary biliary cirrhosis. Fourteen patients were included in a randomized, crossover study. After a 15-day washout period, subjects were followed for three weeks. During the first and third week, patients received 600 mg of rifampin or placebo; no treatment was administered during the second week. Pruritus was subjectively scored on a scale from 0 to 100. With rifampin, pruritus disappeared in 11 patients and partially improved in three; with placebo, only two had a partial response (P less than 0.001). Six patients with a prior poor or no response to cholestyramine improved with rifampin. No changes in biochemical tests or side effects were observed during this period. We conclude that short-term administration of rifampin relieves pruritus in primary biliary cirrhosis. When administered over a period of eight months in an open study, the relief of pruritus was maintained, while one individual developed an allergic reaction. Rifampin appears to be a safe drug in the management of the pruritus of primary biliary cirrhosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although uncommon, drug-induced liver injuries-sometimes progressing to acute liver failure, hemolysis, renal impairment, and alteration in drug metabolism-have all been reported with rifampicin use such that use is avoided in patients with bilirubin levels greater than 2.5 mg/dL, with close follow-up warranted.(195,199)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [195]
In the citing paper
“Rifampicin, a pregnane X receptor agonist, has been used to successfully treat pruritus in patients with PBC in multiple small clinical trials at doses ranging from 150 mg daily to 300 mg twice daily.(193)(194)(195)(196)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [195]
In the citing paper
“Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.182–185”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [184]
Citations
Cites
The two‐period cross‐over clinical trial.
Hills, M., & Armitage, P. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb05903.x · Cited by 1,395
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
THE ESTIMATION OF ANTIPYRINE IN BIOLOGICAL MATERIALS
Brodie, B. B., Axelrod, J., Soberman, R., & Levy, B. B. (1949) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56807-1 · Cited by 409
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231 · cited 7×
“Rifampin may rarely cause serious idiosyncratic hypersensitivity reactions, such as hemolytic anemia, renal failure, and thrombocytopenic purpura (9, 15-18).”
BackgroundInfluentialGrosset, J., & Leventis, S. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s440 · Cited by 218 · cited 3×
“Up to 5% of individuals may have a moderate increase in transaminases, alkaline phosphatase, and bilirubin that normalize even in the presence of continued treatment (12).”
BackgroundRelief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 133 · cited 1×
“H~-histamine blockers (2-5) or procedures such as plasmapheresis and phototherapy (6, 7).”
BackgroundScheuer, P. J., & Lefkowitch, J. H. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199511000-00018 · Cited by 130
Scheuer, P. J., Lal, S., Summerfield, J. A., & Sherlock, S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92381-2 · Cited by 120
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120 · cited 1×
“H~-histamine blockers (2-5) or procedures such as plasmapheresis and phototherapy (6, 7).”
Background
Research works printed but not linked: 1
- Girling D: Hepatitis and other adverse reactions to antituberculous chemotherapy. Bull Int Union Tuber 51:8?12, 1980
Cited by
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“Rifampicin, a pregnane X receptor agonist, has been used to successfully treat pruritus in patients with PBC in multiple small clinical trials at doses ranging from 150 mg daily to 300 mg twice daily.(193-196) Two meta-analyses have reported that rifampicin administration is associated with relief of pruritus in chole…”
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Primary Sclerosing Cholangitis
Lee, Y.-M., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 526
Management of primary biliary cirrhosis
Heathcote, J. E. (2000) · Hepatology · doi:10.1053/he.2000.5984 · Cited by 417
Itch: scratching more than the surface
Twycross, R. (2003) · QJM · doi:10.1093/qjmed/hcg002 · Cited by 407
European S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study
Wolfhagen, F., Sternieri, E., Hop, W., Vitale, G., Bertolotti, M., & Van Buuren, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322521 · Cited by 343
Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
MARSCHALL, H., WAGNER, M., ZOLLNER, G., FICKERT, P., DICZFALUSY, U., GUMHOLD, J., SILBERT, D., FUCHSBICHLER, A., BENTHIN, L., & GRUNDSTROM, R. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 325
A controlled trial of naloxone infusions for the pruritus of chronic cholestasis
Bergasa, N. V., Talbot, T. L., Alling, D. W., Schmitt, J. M., Walker, E. C., Baker, B. L., Korenman, J. C., Park, Y., Hoofnagle, J. H., & Jones, E. A. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90102-5 · Cited by 287
Primary sclerosing cholangitis: Summary of a workshop
LaRusso, N. F., Shneider, B. L., Black, D., Gores, G. J., James, S. P., Doo, E., & Hoofnagle, J. H. (2006) · Hepatology · doi:10.1002/hep.21337 · Cited by 251
European Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Darsow, U., Misery, L., Wallengren, J., Mettang, T., Gieler, U., Lotti, T., Lambert, J., Maisel, P., et al. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1400 · Cited by 253
Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.002 · Cited by 247
Effects of long-term rifampicin administration in primary biliary cirrhosis
Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90335-v · Cited by 235
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202
Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202
Terg, R., Coronel, E., Sordá, J., Muñoz, A. E., & Findor, J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00318-5 · Cited by 199
Self-citationHypothesis The Pruritus of Cholestasis: From Bile Acids to Opiate Agonists
Jones, A. E., & Bergasa, N. V. (1990) · Hepatology · doi:10.1002/hep.1840110526 · Cited by 189
Hohenester, S., Oude-Elferink, R. P. J., & Beuers, U. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 179
Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176
“Only four of 12 studies presented data for the complete resolution of pruritus (63, 64, 67, 70).”
BackgroundKhurana, S., & Singh, P. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01326.x · Cited by 162
“Three of the five trials included in this analysis mention a follow-up after long-term use of rifampin in some of the patients (17, 18, 20).”
BackgroundMethodInfluentialUnderstanding Pruritus in Systemic Disease
Krajnik, M., & Zylicz, Z. (2001) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00256-6 · Cited by 164
Trauner, M., Wagner, M., Fickert, P., & Zollner, G. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155551.37266.26 · Cited by 164
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis
Frezza, M., Surrenti, C., Manzillo, G., Fiaccadori, F., Bortolini, M., & Padova, C. D. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91250-a · Cited by 153
Natural history of pruritus in primary biliary cirrhosis
Talwalkar, J. A., Souto, E., Jorgensen, R. A., & Lindor, K. D. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00134-4 · Cited by 141
Kuiper, E. M. M., van Erpecum, K. J., Beuers, U., Hansen, B. E., Thio, B. H., de Man, R. A., Janssen, H. L. A., & van Buuren, H. R. (2010) · Hepatology · doi:10.1002/hep.23821 · Cited by 132
Itch: Pathogenesis and treatment
Sutaria, N., Adawi, W., Goldberg, R., Roh, Y. S., Choi, J., & Kwatra, S. G. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.07.078 · Cited by 130
Pruritus in cholestatic and other liver diseases
Mela, M., Mancuso, A., & Burroughs, A. K. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01458.x · Cited by 129
Pathogenesis and Treatment of Pruritus in Cholestasis
Kremer, A. E., Beuers, U. H., Elferink, R. P. J. O., & Pusl, T. (2008) · Drugs · doi:10.2165/00003495-200868150-00006 · Cited by 143
Novel therapeutic targets in primary biliary cirrhosis
Dyson, J. K., Hirschfield, G. M., Adams, D. H., Beuers, U., Mann, D. A., Lindor, K. D., & Jones, D. E. J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.12 · Cited by 120
Transcriptional regulation of hepatic stellate cells
Mann, J., & Mann, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.011 · Cited by 119
“Rifampicin is currently prescribed to patients with primary biliary cirrhosis in order to control itch, and it has been shown to reduce serum levels of alkaline phosphatase in clinical trials [188,189].”
BackgroundPrimary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T., & Cappell, M. S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 138
Bergasa, N. V. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.004 · Cited by 128
Rifampin relieves pruritus in children with cholestatic liver disease
Cynamon, H. A., Andres, J. M., & Iafrate, R. P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90027-x · Cited by 109
Benign recurrent intrahepatic cholestasis
Luketic, V. A., & Shiffman, M. L. (2004) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00133-8 · Cited by 110
Pathophysiology and current management of pruritus in liver disease
Kremer, A. E., Elferink, R. P. J. O., & Beuers, U. H. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2010.10.007 · Cited by 119
Use of Rifampin for Severe Pruritus in Children with Chronic Cholestasis
Yerushalmi, B., Sokol, R. J., Narkewicz, M. R., Smith, D., & Karrer, F. M. (1999) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.1999.tb02448.x · Cited by 104
Diagnostik und Therapie des hepatozellulären Karzinoms
Greten, T. F., Malek, N. P., Schmidt, S., Arends, J., Bartenstein, P., Bechstein, W. O., Bernatik, T., Bitzer, M., Chavan, A., Dollinger, M. M., et al. (2013) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0033-1355841 · Cited by 131
Approach to a Patient with Elevated Serum Alkaline Phosphatase
Siddique, A., & Kowdley, K. V. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.012 · Cited by 98
“Rifampin decreases hepatic uptake and facilitates renal elimination of bile acids.(190) The recommended dose is 300 to 600 mg/d.”
BackgroundRifampicin in the treatment of severe intrahepatic cholestasis of pregnancy
Geenes, V., Chambers, J., Khurana, R., Shemer, E. W., Sia, W., Mandair, D., Elias, E., Marschall, H.-U., Hague, W., & Williamson, C. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.020 · Cited by 98
“This study is that it is the first report of its kind, although rifampicin has been used with good effect in other cholestatic liver disorders, including primary biliary cirrhosis and childhood cholestatic syndromes [8–14].”
BackgroundReview article: the use of potentially hepatotoxic drugs in patients with liver disease
GUPTA, N. K., & LEWIS, J. H. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03822.x · Cited by 96
Receptors, cells and circuits involved in pruritus of systemic disorders
Kremer, A. E., Feramisco, J. D., Reeh, P. W., Beuers, U. H., & Elferink, R. P. J. O. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.007 · Cited by 103
Millington, G. W. M., Collins, A., Lovell, C. R., Leslie, T. A., Yong, A. S. W., Morgan, J. D., Ajithkumar, T., Andrews, M. J., Rushbook, S. M., Coelho, R. R., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16117 · Cited by 92
Cançado, E. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00353-0 · Cited by 91
Effect of oral naltrexone on pruritus in cholestatic patients
Mansour-Ghanaei, F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i7.1125 · Cited by 89
“On the other hand, the VAS system can control pruritus quite well [4, 8-12 , 42]”
BackgroundPharmacological interventions for pruritus in adult palliative care patients
Siemens, W., Xander, C. J., Meerpohl, J. J., Buroh, S., Antes, G., Schwarzer, G., & Becker, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008320.pub3 · Cited by 93
Karlsen, T. H., Vesterhus, M., & Boberg, K. M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12581 · Cited by 86
Pruritus and fatigue in primary biliary cirrhosis
Bergasa, N. V., Mehlman, J. K., & Jones, E. A. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0109 · Cited by 83
New perspectives for the treatment of cholestasis: Lessons from basic science applied clinically
Boyer, J. L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.12.001 · Cited by 95
Pathogenesis and Management of Pruritus in PBC and PSC
Kremer, A. E., Namer, B., Bolier, R., Fischer, M. J. M., Elferink, R. P. J. O., & Beuers, U. H. (2015) · Digestive Diseases · doi:10.1159/000440829 · Cited by 89
Advances in Pathogenesis and Management of Pruritus in Cholestasis
Kremer, A. E., Bolier, R., van Dijk, R., Elferink, R. P. J. O., & Beuers, U. H. (2014) · Digestive Diseases · doi:10.1159/000360518 · Cited by 90
The effects of alcohol and drug abuse on the skin
Liu, S. W., Lien, M. H., & Fenske, N. A. (2010) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2010.03.024 · Cited by 78
Subhypnotic doses of propofol relieve pruritus associated with liver disease
Borgeat, A., Wilder‐Smith, O. H. G., & Mentha, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90858-a · Cited by 77
Diagnosis and Management of Cholestatic Liver Disease
Heathcote, E. J. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.008 · Cited by 93
Stimulation of bile acid 6α-hydroxylation by rifampin
Wietholtz, H., Marschall, H., Sjövall, J., & Matern, S. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80268-6 · Cited by 81
Pain as a complication of use of opiate antagonists for symptom control in cholestasis
Mcrae, C. A., Prince, M. I., Hudson, M., Day, C. P., James, O. F. W., & Jones, D. E. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00879-5 · Cited by 73
Gossard, A. A., & Talwalkar, J. A. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.09.002 · Cited by 77
The rational use of potentially hepatotoxic medications in patients with underlying liver disease
Lewis, J. H. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.2.159 · Cited by 73
A controlled trial of ondansetron in the pruritus of cholestasis
O'Donohue, J. W., Pereira, S. P., Ashdown, A. C., Haigh, C. G., Wilkinson, J. R., & Williams, R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02430.x · Cited by 71
Evolving Concepts of the Pathogenesis and Treatment of the Pruritus of Cholestasis
Jones, E. A., & Bergasa, N. V. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/747495 · Cited by 70
Pruritus in Chronic Cholestatic Liver Disease
Bunchorntavakul, C., & Reddy, K. R. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.010 · Cited by 75
Pruritus in systemic disease: mechanisms and management
Etter, L., & Myers, S. A. (2002) · Dermatologic Clinics · doi:10.1016/s0733-8635(02)00011-6 · Cited by 65
Molecular mechanisms of cholestasis
Zollner, G., & Trauner, M. (2006) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-006-0312-7 · Cited by 82
Recent Advances in Pathophysiology and Current Management of Itch
Greaves, M. W. (2007) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v36n9p788 · Cited by 69
Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities
Tarikçi, N., Kocatürk, E., Güngör, Ş., Topal, İ. O., Can, P. K., & Singer, R. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/803752 · Cited by 67
“The reported decrease in pruritus associated with phenobarbital may be caused by sedation [55, 56].”
BackgroundPruritus in Primary Biliary Cirrhosis: Pathogenesis and Therapy
Bergasa, N. V. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.013 · Cited by 60
Bergasa, N. V. (2011) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2011.04.009 · Cited by 59
Itch in systemic disease: therapeutic options
Greaves, M. W. (2005) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2005.00036.x · Cited by 58
Prolonged hepatic cholestasis after flucloxacillin therapy
Turner, I. B., Eckstein, R. P., Riley, J. W., & Lunzer, M. R. (1989) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1989.tb139652.x · Cited by 55
Pathogenesis and Treatment of Pruritus
Greaves, M. W. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-010-0117-z · Cited by 57
Palliative Care for Patients with End-Stage Liver Disease Ineligible for Liver Transplantation
Sánchez, W., & Talwalkar, J. A. (2006) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2005.12.007 · Cited by 58
Cholestatic pruritus: Emerging mechanisms and therapeutics
Patel, S. P., Vasavda, C., Ho, B. K., Meixiong, J., Dong, X., & Kwatra, S. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.04.035 · Cited by 63
Prince, M. I., Mitchison, H. C., Ashley, D., Burke, D. A., Edwards, N., Bramble, M. G., James, O. F. W., & Jones, D. E. J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01398.x · Cited by 52
Effect of rifampicin in the treatment of pruritus in hepatic cholestasis.
Gregorio, G. V., Ball, C., Mowat, A. P., & Mieli‐Vergani, G. (1993) · Archives of Disease in Childhood · doi:10.1136/adc.69.1.141 · Cited by 54
‘Out‐patient’ albumin dialysis for cholestatic patients with intractable pruritus
Leckie, P., Tritto, G., Mookerjee, R., Davies, N., Jones, D., & Jalan, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.04994.x · Cited by 51
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 53
“Rifampin improves pruritus [53-56] and decreases serum concentrations of BAs [53,57], ALP [53,57], aminotransferases [57] and bilirubin [53].”
BackgroundPruritus and fatigue in primary biliary cirrhosis
Bergasa, N. V. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00105-3 · Cited by 52
TURNER, I. B., MYSZOR, M., MITCHISON, H. C., BENNETT, M. K., BURT, A. D., & JAMES, O. F. W. (1994) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1994.tb01237.x · Cited by 47
Clinical features and management of primary biliary cirrhosis
Crosignani, A. L., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 51
Pruritis associated with cholestasis: A review of pathogenesis and management
Khandelwal, M., & Malet, P. F. (1994) · Digestive Diseases and Sciences · doi:10.1007/bf02090052 · Cited by 46
Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review
Trivedi, H. D., Lizaola‐Mayo, B., Tapper, E. B., & Bonder, A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.01.037 · Cited by 47
Nuclear Receptors CAR and PXR; therapeutic targets for cholestatic liver disease
Kakizaki, S. (2011) · Frontiers in Bioscience · doi:10.2741/3893 · Cited by 44
“Rifampicin, PXR ligand induces the hepatic metabolism in PBC patients to ameliorate the symptoms of pruritus (93) and lower the serum concentrations of alkaline phosphatase, a marker of cholestatic liver disease, and BAs (94, 95).”
BackgroundSymptoms of PBC – Pathophysiology and management
Khanna, A., Leighton, J., Wong, L. L., & Jones, D. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.007 · Cited by 49
Extrahepatic manifestations of cholestasis
Glasová, H., & Beuers, U. H. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02717.x · Cited by 49
Medical and Nutritional Management of Cholestasis in Infants and Children
Feranchak, A. P., & Sokol, R. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.012 · Cited by 45
The hypertensive lower esophageal sphincter
Freidin, N., Traube, M., Mittal, R. K., & McCallum, R. W. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536375 · Cited by 40
Pharmacological interventions for pruritus in adult palliative care patients
Xander, C. J., Meerpohl, J. J., Galandi, D., Buroh, S., Schwarzer, G., Antes, G., & Becker, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008320.pub2 · Cited by 45
Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Richards, D., Storey, J., Dukes, G., Gilchrist, K., Vallow, S., Alexander, G. J., et al. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0481-9 · Cited by 39
Webb, G. J., Rahman, S. R., Levy, C., & Hirschfield, G. M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14579 · Cited by 42
“Nonrifampicin medications (n + IQR) 5 (3-6) 4 (3-6) 0.”
Cholestasis-Associated Pruritus and Its Pruritogens
Langedijk, J., Beuers, U. H., & Elferink, R. P. J. O. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.639674 · Cited by 49
Innovative Management of Pruritus
Feramisco, J. D., Berger, T. G., & Steinhoff, M. S. (2010) · Dermatologic Clinics · doi:10.1016/j.det.2010.03.004 · Cited by 41
Pruritus as a symptom of hepatitis C
Fisher, D. A., & Wright, T. L. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70072-9 · Cited by 39
Metadata
- Authors
- Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P.
- Affiliations
- Hospital Italiano de Buenos Aires (AR)
- Venue
- Digestive Diseases and Sciences
- Published
- 1991-02
- Volume
- 36
- Issue
- 2
- Pages
- 216-220
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2075314339
- Cited by
- 267
- References
- 31
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 9 · 2017: 12 · 2016: 9 · 2015: 14 · 2014: 8 · 2013: 6 · 2012: 9
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- pruritus, primary biliary cirrhosis, rifampicin, cholestasis, cholestyramine, pruritus management, drug safety, allergic reactions
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bilirubin, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Rifampin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.